ivabradine NDC 70710-1471

NDC codes

FDA NDC Directory

Product NDC (as listed)70710-1471Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70710-1471Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70710-1471-6	70710147106	60 TABLET in 1 BOTTLE (70710-1471-6)Marketed from Jul 2, 2024
70710-1471-8	70710147108	180 TABLET in 1 BOTTLE (70710-1471-8)Marketed from Jul 2, 2024

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): ivabradine
Generic name (nonproprietary): ivabradine
Active ingredients: Ivabradine hydrochloride — 5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Zydus Pharmaceuticals USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213442
Marketing start: Jul 2, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Hyperpolarization-activated Cyclic Nucleotide-gated Channel Antagonists (Mechanism)
Identifiers: Product ID 70710-1471_cbea8583-e207-402a-b79a-83ff14a3fa9bSPL ID cbea8583-e207-402a-b79a-83ff14a3fa9bSPL set ID 89134202-971b-4413-a9c9-d31a5c29722bRxCUI 1649485, 1649493UNII TP19837BZK
Pharmacologic class: Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470710147106 followed by a unit qualifier and the quantity

Package 70710-1471-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 1, 2023.

Indications (excerpt from the label)

Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 ) 1.1 Heart Failure in Adult Patients Ivabradine tablets are indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-bloc…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 213442

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 213442
Product	Strength	Form · route	Labeler	Product NDC
ivabradine	Ivabradine hydrochloride 5 mg/1	TabletOral	Zydus Lifesciences Limited	70771-1863
ivabradine	Ivabradine hydrochloride 7.5 mg/1	TabletOral	Zydus Lifesciences Limited	70771-1864
ivabradine	Ivabradine hydrochloride 7.5 mg/1	TabletOral	Zydus Pharmaceuticals USA Inc.	70710-1472